Chuen-Pei Ng, Ph.D.
Affiliations: | 2001 | University of California, Los Angeles, Los Angeles, CA |
Area:
Cell Biology, Oncology, ImmunologyGoogle:
"Chuen-Pei Ng"Parents
Sign in to add mentor| Benjamin Bonavida | grad student | 2001 | UCLA | |
| (Molecular determinants of prostate tumor resistance to immunotherapy and sensitization to death receptor -mediated apoptosis.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Jia RR, Gou YL, Ho LS, et al. (2005) Anti-apoptotic activity of Bak Foong Pills and its ingredients on 6-hydroxydopamine-induced neurotoxicity in PC12 cells. Cell Biology International. 29: 835-42 |
| Ng CP, Bonavida B. (2002) X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Molecular Cancer Therapeutics. 1: 1051-8 |
| Ng CP, Zisman A, Bonavida B. (2002) Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. The Prostate. 53: 286-99 |
| Ng CP, Bonavida B. (2002) A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance. Advances in Cancer Research. 85: 145-74 |
| Alas S, Ng CP, Bonavida B. (2002) Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 836-45 |
| Zisman A, Ng CP, Pantuck AJ, et al. (2001) Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis. Journal of Immunotherapy (Hagerstown, Md. : 1997). 24: 459-71 |
| Jazirehi AR, Ng CP, Gan XH, et al. (2001) Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 3874-83 |
| Van Ophoven A, Ng CP, Patel B, et al. (1999) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) for treatment of prostate cancer: first results and review of the literature. Prostate Cancer and Prostatic Diseases. 2: 227-233 |
| Bonavida B, Ng CP, Jazirehi A, et al. (1999) Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review). International Journal of Oncology. 15: 793-802 |
| Uslu R, Borsellino N, Frost P, et al. (1997) Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 3: 963-72 |